How the medical device process really works.
From a clinical insight to a product hospitals buy: the stages, FDA pathways, funding milestones, partners and decisions every MedTech startup and entrepreneur faces, and how to sequence them so capital buys real progress.
It takes an ecosystem to build a medical device.
The founder owns the vision, but a device reaches patients only when many specialized disciplines contribute at the right moment. One startup. Many capabilities. Not all of them needed on day one.
Clinical
- Physicians and nurses
- Key opinion leaders
- End users and patients
Product development
- Engineering & industrial design
- Human factors
- Program management
Quality & regulatory
- Quality management system
- Regulatory strategy
- Risk management & design controls
Testing
- Bench and performance testing
- Preclinical and clinical studies
- Biocompatibility, sterilization, packaging
Manufacturing
- Contract manufacturers
- Suppliers and tooling
- Process engineering
Business
- Market research
- Reimbursement
- Finance, investors & fundraising
Commercial
- Sales and distribution
- Marketing
- Strategic partnerships
Where Birch Design fits
We lead the product, regulatory and manufacturing threads and bring in trusted suppliers, test labs, specialists and contract manufacturers, so you don’t have to hire every function.
Early on, most startups are deep in engineering and clinical work, lightly involved in quality, regulatory and business planning, and barely engaged with testing, manufacturing and commercial partners. The job is to bring each one in before it becomes the bottleneck, not after.
Not every medical device project is the same.
Before choosing a partner or a budget, be clear about what kind of project you are running and where you ultimately want the company or technology to go.
| Project type | The question it answers | Typical starting point |
|---|---|---|
| Full development | How do we turn this opportunity into a complete commercial product? | A clinical need or early concept; no finished design |
| Feasibility / prototype | Can this concept actually work? | An idea with high technical or usability risk |
| Design transfer / build to print | How do we reliably manufacture what has been designed? | A mature design with drawings, BOM and specifications |
| Next-generation development | How do we make the current product better? | An existing product with known improvement goals |
| Animal study program | What evidence do we need before moving forward clinically? | Design-representative devices and a study hypothesis |
| Clinical trial program | How do we demonstrate performance and clinical value in real-world use? | Verified devices and a regulatory strategy |
Build to scale
The startup intends to develop the complete product, own the regulatory strategy, transfer into manufacturing, build commercial operations and launch.
Requires more capital, a larger internal organization and strong long-term manufacturing and commercial partnerships.
Build to partner or exit
The startup intends to demonstrate feasibility, develop intellectual property, generate preclinical or clinical evidence and reach a value inflection point, then license or sell.
The company may not need to build the entire commercialization infrastructure itself.
The development plan should match the exit strategy. Many founders keep both options open through feasibility.
The eight stages of medical device development.
Each stage answers a specific question and produces evidence the next stage depends on. Under FDA design controls, much of that evidence must be documented as you go, which is why the order matters.
Concept & user needs
Define the clinical problem, the users, the use environment and what the device must do. This is where the business case and the regulatory hypothesis start.
- User needs and intended use
- Initial design inputs and requirements
- Early regulatory and reimbursement hypothesis
Feasibility
Build proof-of-concept prototypes and test the highest-risk technical and usability questions on the bench, in models or in cadaver labs, with early clinician feedback.
- Functional prototypes
- Bench data on the riskiest questions
- Clinician feedback and a clearer architecture
Design & development
Iterate the design under design controls: design reviews, risk management (ISO 14971), design for manufacturability and supplier selection, ending at design freeze.
- Design history file and risk file
- DFM review and first cost-of-goods estimate
- Design-representative builds
Verification & validation
Prove the design meets every requirement (verification) and every user need (validation): performance testing, biocompatibility, sterilization and packaging validation, software and human factors.
- V&V protocols and reports
- Biocompatibility, sterilization and shelf-life data
- Formative and summative usability studies
Clinical evidence
Generate the preclinical and clinical evidence the pathway requires, from animal studies to first-in-human and pivotal trials, with IRB and, when needed, FDA IDE approval.
- Animal and cadaver study reports
- IDE or IRB approvals and study protocols
- Clinical data and study report
Regulatory submission
Assemble and submit the 510(k), De Novo or PMA, respond to FDA questions, and confirm your quality system is ready for the Quality Management System Regulation (QMSR).
- Pre-Submission feedback from FDA
- Submission package and responses
- Clearance, grant or approval
Design transfer
Move the design into repeatable production with a contract manufacturer or internal line: process development, tooling, fixtures, IQ/OQ/PQ validation and supplier qualification.
- Manufacturing process and work instructions
- Process validation (IQ/OQ/PQ)
- Qualified suppliers and pilot builds
Launch & scale
Prepare launch inventory, commercial partners and training, then scale volume with yield improvement and, when it pays off, automation, while post-market processes run.
- Commercial supply and distribution plan
- Post-market surveillance and complaint handling
- Scale-up and automation roadmap
How FDA classifies and clears medical devices.
Your device’s risk class largely determines the regulatory pathway, and the pathway drives the evidence, budget and timeline for everything upstream.
Low risk
General controls. Most Class I devices are exempt from premarket notification but still need registration, listing and quality requirements.
Moderate risk
General and special controls. Most require a 510(k) showing substantial equivalence to a legally marketed predicate device.
High risk
Life-supporting, life-sustaining or implantable devices with significant risk. Most require Premarket Approval (PMA) with clinical data.
| Pathway | When it applies | Typical evidence | FDA review goal | FY2027 user fee |
|---|---|---|---|---|
| Exempt | Many Class I and some Class II devices | Design controls where required, labeling, registration | No premarket review | Annual establishment registration $13,785 |
| 510(k) | A predicate device exists | Bench performance, biocompatibility, software, sometimes clinical | 90 FDA days | $28,653 ($7,163 small business) |
| De Novo | Novel, low-to-moderate risk, no predicate | Bench plus often clinical data; proposed special controls | 150 FDA days | $191,020 ($47,755 small business) |
| PMA | Class III, high risk | Valid scientific evidence, usually a pivotal clinical study; manufacturing inspection | 180 FDA days (longer with an advisory panel) | $636,732 ($159,183 small business) |
Pre-Submission (Q-Sub)
Free written FDA feedback on your pathway, testing and study plans, typically about 70 days after FDA receives the request. The best-value regulatory step most startups can take.
Investigational Device Exemption
A significant-risk clinical study in the U.S. needs an approved IDE from FDA plus IRB approval before enrolling patients.
Quality system (QMSR)
Since February 2, 2026, FDA’s Quality Management System Regulation incorporates ISO 13485:2016 by reference. Size your QMS to your stage, but start design controls early.
“FDA days” exclude time a submission is on hold waiting for your answers, so real calendar time is usually longer. Fees are FDA’s fiscal year 2027 rates (October 1, 2026 to September 30, 2027). Sources: FDA, Medical Device User Fee Rates for FY2027, FDA Q-Submission Program, FDA QMSR. General information, not regulatory advice for a specific device.
Spend to the next value milestone.
For a startup, technical decisions are business decisions. The goal is not just to move the product forward; it is to reach the next meaningful milestone without exhausting time or capital.
Investment should rise as confidence rises. Small, focused spending while uncertainty is high; larger commitments to tooling, validation and manufacturing once the riskiest questions are answered.
Concept & feasibility
- Early engineering
- Initial prototypes
- Technical evaluation
Development & verification
- Design and development
- Iterative prototypes
- Testing and studies
Transfer, tooling & validation
- Manufacturing development
- Tooling and process development
- Validation and regulatory prep
Production & commercialization
- Full manufacturing
- Supply chain
- Commercial launch
A startup with 18 months of runway
An entrepreneur has raised $1.5M, has $1.2M in the bank and a team of three. The next funding round depends on one thing: proving the core design works.
Build the organization now
Commit roughly $700K over the next year to hire full-time engineers, set up internal quality and regulatory infrastructure, start manufacturing development and add early commercial resources.
Fund the next milestone
Commit about $150K to a focused four-month feasibility program: $60K fractional engineering and program leadership, $45K prototype iterations, $20K bench testing, $15K clinician evaluation and $10K quality and regulatory guidance.
Hypothetical figures for illustration only. Your numbers depend on the device, pathway and team. Model yours in the Journey Planner.
Who should help you build it?
There are four ways to turn a medical innovation into a real device. Most successful startups use more than one, adding infrastructure as the product matures.
Internal team
Full-time hires give control and continuity, but create significant fixed burn before technical feasibility is established.
Best once the product and funding are stableConsultants & fractional experts
Senior expertise that expands and contracts with the need. You pay for the work, not the overhead.
Best early, and for specialized gapsProduct development firm
Broad engineering capability under one roof, with moderate flexibility and moderate-to-high project cost.
Best for complex, well-funded buildsContract manufacturer
A higher-commitment partner built to eventually manufacture your product, often with design and prototyping capacity.
Best as the design matures toward transferStart lean. Add infrastructure as the product matures.
The network is part of the capability
No development company has every capability under one roof. A strong partner is valuable not only for what it can do internally, but for who it can bring into the program: clinical experts, test labs, sterilization and packaging suppliers, tooling vendors, contract manufacturers, regulatory specialists and investors. Trusted introductions save both time and risk.
The right partner for the next stage, not every stage.
Your first engagement does not need to cover the entire product lifecycle. Many long-term development relationships begin with one clearly defined project.
Targeted project
Solve one defined problem.
Milestone project
Reach a specific development milestone.
Ongoing support
Provide recurring engineering or program resources.
Full development
Take responsibility for a major portion of product development.
A staged engagement in practice
Instead of signing a $750K full-development contract up front, a startup funds one phase at a time and decides at each gate whether the next phase is justified.
Improve the core mechanism, build five prototypes, bench-test performance and recommend next steps. Result: you learn whether the core technology deserves more investment.
Funded only after feasibility passes: design iterations under design controls, DFM and design-representative builds.
Formal testing, documentation and manufacturing preparation once the design is stable.
Which contract model fits?
| Model | Best when | Example | Advantage | Trade-off |
|---|---|---|---|---|
| Time & materials | The scope is still evolving | “Help us iterate the mechanism.” | High flexibility | Less total-cost certainty |
| Defined milestones | The outcome can be clearly described | Deliver 10 design-representative prototypes for bench testing | Better budget and schedule visibility | Scope changes may need change orders |
| Fractional / retained | Continuity is needed without a full-time hire | A fractional program leader, about 10 hours a week | Consistent access to experience | The startup still coordinates multiple resources |
| Development + manufacturing | The partner also has production capability | A manufacturer finishes the design because it wants the production business | Continuity into production | A larger commitment, earlier |
The more defined the work becomes, the easier it is to fix cost, schedule and responsibility. For manufacturers, the long-term value is often production, not the engineering project. Example figures are illustrative.
Your program is the whole company to you. To a partner, it is one of many.
In an illustrative year, a development or manufacturing partner might support ten programs, hit six major milestones, run three transfer projects and see one or two commercial launches. Make it easy for them to know what matters most.
- Clear priorities
- Fast decisions
- Defined milestones
- Consistent communication
- One accountable program lead on your side
Why development projects stop, and how to see it coming.
A promising device can fail for reasons that have nothing to do with the original idea. The best teams look for weak signals early, before committing significantly more capital, time or resources.
Can it work?
Performance, reliability, safety and manufacturability against the requirements.
Will people adopt it?
Clinician preference, workflow fit, hospital value analysis and reimbursement.
Should we keep investing?
Cost of goods, margin, capital required, time to market and exit potential.
Feasibility gate for a steerable catheter
- Steering performancePASS
- Torque transmissionPASS
- Clinician feedbackPASS
- Estimated unit costFAIL
Technically ready for the next phase; commercially, the margin does not work at the current design.
The startup now has options
- Reduce product cost through design for manufacturability
- Change the design architecture
- Target a different market or price point
- Find a manufacturing partner with a better cost structure
- License the technology
- Stop the program
In this example the team redesigns the handle to cut cost before committing to verification, the cheapest point to make that change. A successful feasibility result does not mean the design is finished; it means the next decision is clearer.
Choose the right manufacturing partner, not just the first one available.
Partner selection matters more as the product approaches scalable manufacturing. Balance technical capability, medical device experience, communication, schedule, cost and long-term fit.
Define what you actually need
- What stage is the product in?
- What problem are we solving, and what deliverable do we need?
- Which budget and schedule constraints matter?
- Development, transfer, testing or manufacturing?
Build a short list
- Trusted referrals and advisors
- Industry relationships and prior experience
- Clinicians, suppliers and manufacturers
- Conferences and industry groups
Evaluate technical fit
- Have they built similar products?
- Do they understand the technology?
- Right engineering and process capabilities?
- Can they support testing, documentation and scale?
Evaluate working fit
- Communication: do they explain problems clearly?
- Responsiveness: can they decide quickly?
- Transparency: will they raise issues early?
- Ownership: partner, or task-taker?
A design transfer opportunity
- Mature design: drawings, BOM, specifications
- Defined requirements and manufacturing approach
- Tooling, process, quality and validation scope identified
- Clearer commercial opportunity
A full development opportunity
- Concept and initial design only
- Unknown engineering effort and potential redesign
- Technical, manufacturing and regulatory uncertainty
- Unclear production volumes and open-ended scope
The more defined your product, the easier it is for manufacturers to compete for the work, and the better your terms.
Know the manufacturer in front of you.
Almost every contract manufacturer advertises both design and manufacturing. If they can manufacture, they want to manufacture: their business model is built around production. Large, stable production programs rarely appear out of nowhere, so many build in-house design and prototyping to keep a steady flow of growing customers.
For a startup, that means understanding how your product and your ask fit their business model. Labels like CDMO, CMO or CDO matter less than what the company actually does well. We help founders read those signals, build the short list and run the evaluation.
The product is ready. Now the market has to be ready.
A device must do more than meet technical and regulatory requirements. It has to fit the U.S. healthcare market: how it is purchased, adopted, paid for and used. A cleared product can still fail commercially.
Clinician
Fewer steps, better outcomes or faster procedures, without new training burden.
Hospital / buyer
Value analysis committees weigh device cost against procedure time, outcomes and supplies.
Payer
Existing coding and payment may cover it, or new reimbursement evidence may be needed.
Distributor / partner
A specialized distributor can reach early accounts faster than building a direct sales force.
Patient
Shorter, safer or simpler care that patients and clinicians can feel.
Why devices get adopted
Clinical value
Measurably better for the patient or the procedure.
Economic value
Savings or revenue that justify the price for the hospital.
Workflow fit
Works within existing labs, staff roles and supplies.
Commercial execution
A credible plan to sell, distribute, train and support.
Late in development, the biggest remaining risk is often no longer technical. It is commercial execution. Building adoption hypotheses for each stakeholder early lets you test them alongside the engineering.
Right problem. Right partner. Right time.
Four principles to guide a medical device company through every stage of the journey.
Define the next milestone
Not the entire future. Know what problem needs solving, what stage you are in and which milestone matters next.
Match the partner to the problem
Not every partner needs to stay forever. Choose the project first, then the partner.
Increase commitment as confidence grows
Smaller, flexible, targeted spending early; larger infrastructure and manufacturing investment once risk is reduced.
Build the network before you need it
Relationships shorten the next step. Use the ecosystem instead of trying to own everything.
One startup, many relationships
No single organization carries a device from clinical need to market adoption. The startup stays at the center while the supporting team evolves.
Startups don’t succeed because they have every capability.
They succeed because they know which capability they need next. Birch Design helps founders decide, then delivers it, from feasibility and FDA strategy to design transfer and contract manufacturer selection.